To The Moon

$Medtronic PLC(MDT)$, a major player in the medical technology sector, is scheduled to report its fiscal Q1 2026 financial results on Tuesday, August 19, 2025, before the market opens.

Revenue: The Zacks Consensus Estimate for Q1 2026 revenue is $8.37 billion, which would represent a year-over-year increase of about 5.7%.

Earnings per Share (EPS): Analysts project adjusted earnings of $1.23 per share, which is flat compared to the same quarter last year.

Medtronic (MDT) Fiscal Q4 2025 Earnings: A Summary and Key Lessons

Medtronic closed out its fiscal year 2025 on a high note, reporting a strong fourth quarter that exceeded analyst expectations for both revenue and earnings per share (EPS). The company demonstrated sustained growth momentum driven by its strategic focus on key product franchises and a disciplined approach to managing its operations.

Summary of Q4 2025 Performance

Financial Results: Medtronic reported Q4 revenue of $8.93 billion, an increase of 3.9% on a reported basis and 5.4% organically. This beat the Zacks Consensus Estimate. Adjusted EPS came in at $1.62, an 11% year-over-year increase, also surpassing analyst projections. This marked the company's tenth consecutive quarter of mid-single-digit organic revenue growth.

Segmental Highlights:

Cardiovascular: This segment was a standout performer, with revenue accelerating to 8% growth. Key drivers included the Cardiac Ablation Solutions (CAS) business, which saw a nearly 30% increase in revenue, and the successful launch and adoption of the Pulsed Field Ablation (PFA) products. The Cardiac Rhythm Management and Structural Heart businesses also delivered strong results.

Neuroscience: The segment grew by 3.7% organically, with notable strength in Neuromodulation, which grew in the double digits, and Cranial & Spinal Technologies, which saw high-single-digit growth in the U.S.

Diabetes: This business also showed double-digit organic growth, driven by strong adoption of its MiniMed 780G automated insulin delivery system and Simplera Sync sensor. The company reiterated its intention to spin off the diabetes business into a separate public company.

Profitability and Margins: Medtronic translated its revenue growth into leveraged earnings, with its adjusted operating margin expanding by 90 basis points, reflecting effective cost management and operational efficiency.

Dividend Increase: In a show of confidence, the company announced its 48th consecutive year of a dividend increase, raising the quarterly amount to $0.71 per share.

Lessons from the Fiscal Year 2026 Guidance

While Medtronic's Q4 2025 performance was strong, the guidance provided for the upcoming fiscal year (FY26) offered important lessons for investors. The market's reaction to guidance is often more impactful than the past quarter's results, and this was evident in Medtronic's stock performance post-earnings.

Lesson 1: The "Backend-Loaded" Growth Story. Medtronic guided for full-year FY26 organic revenue growth of approximately 5% and diluted non-GAAP EPS in the range of $5.50 to $5.60. However, the company indicated that this growth will be "backend-loaded." This means that due to factors like continued investments in growth areas and a strong foreign exchange headwind in the first quarter, the company expects more modest growth in the initial part of the year, with an acceleration in the latter half. The key takeaway for investors is to manage expectations for early quarters and to look for signs that the momentum is indeed building as the year progresses.

Lesson 2: The Importance of Diversified Growth Drivers. The company's performance was not reliant on just one or two products but was a result of strong contributions from a wide range of franchises. From Pulsed Field Ablation in cardiology to the MiniMed 780G in diabetes and the Inceptiv spinal cord stimulator in neuroscience, Medtronic's diversified product pipeline is a key factor in its durable growth. The lesson here is to analyze the performance of individual segments, as consistent, broad-based growth signals a healthy and resilient business model.

Lesson 3: Navigating Macroeconomic Headwinds. Medtronic's guidance explicitly factored in potential headwinds, including the impact of foreign currency fluctuations and U.S.-China tariffs. The company provided a detailed breakdown of how these external factors could affect its operating profit and EPS, demonstrating the importance of active mitigation strategies. The lesson for investors is to be aware that even strong companies are not immune to global economic pressures, and to pay close attention to management's plans for addressing them.

Medtronic's Q4 2025 report was a solid demonstration of the company's ability to execute on its strategy and deliver on its commitments. However, the guidance for FY26 served as a reminder that the path to growth is not always linear and that investors must consider both the company's strong fundamentals and its ability to navigate external macroeconomic challenges.

Analysis of Medtronic (MDT) Upcoming Fiscal Q1 2026 Earnings

Earnings Surprise History: Medtronic has a strong track record of beating earnings estimates, with an average surprise of 2.21% over the last four quarters. However, the EPS estimates for this quarter have been trending downward over the past 90 days, suggesting some challenges may be anticipated by analysts.

Key Metrics for Investors to Watch

Beyond the headline numbers of revenue and EPS, investors should pay close attention to the following key metrics to get a more comprehensive picture of the company's performance:

Segment Performance: Medtronic's business is organized into four main segments:

Cardiovascular: Analysts are expecting strong growth here, particularly in areas like Coronary & Peripheral Vascular, with a projected revenue increase of about 2.5% year-over-year globally.

Medical Surgical: This segment's U.S. revenue growth is expected to be modest, with a projected increase of 0.6%.

Neuroscience: This is an important growth driver for the company. Watch for strong growth in Neuromodulation, with analysts projecting a 7.4% increase in global revenue, and Cranial & Spinal Technologies, with a projected 5% increase.

Diabetes: The company has previously announced its intent to separate its Diabetes business. Any updates on this process, as well as the segment's performance, will be of interest to investors.

Profitability and Margins: Given the noted headwinds from inflation and geopolitical pressures, as well as elevated raw material and labor costs, it will be crucial to see how these factors have impacted Medtronic's gross and net profit margins.

Guidance: Medtronic's outlook for the remainder of fiscal year 2026 will be a major market driver. The company's prior full-year guidance for fiscal 2026 included adjusted EPS in the range of $5.50 to $5.60 and organic sales growth of approximately 5%. Any revision to this guidance, either up or down, could significantly impact the stock price.

Foreign Exchange Impact: Medtronic has a significant international presence. The company previously anticipated an unfavorable foreign exchange impact of 1-2% on its quarterly revenues. The actual impact will be an important metric to watch.

Product Pipeline and Strategic Initiatives: Pay attention to any updates on key product launches, clinical trials, or strategic initiatives. For example, the adoption of new products like the Aurora EV-ICD and Micra leadless pacemaker, as well as progress with the Hugo robotic platform, are key to the company's long-term growth story.

Medtronic (MDT) Price Target

Based on 27 analysts from Tiger Brokers offering 12 month price targets for Medtronic in the last 3 months. The average price target is $97.10 with a high forecast of $112.45 and a low forecast of $78.00. The average price target represents a 4.39% change from the last price of $93.02.

Short-Term Trading Opportunities Post-Earnings

Trading Medtronic stock around earnings presents both opportunities and risks. The stock has a history of beating earnings, which could lead to a positive price reaction. However, the company's stock has also experienced post-earnings declines even after reporting a beat, as seen after its Q4 fiscal 2025 report. This suggests that the market's reaction is highly dependent on more than just the headline numbers, with guidance and specific segment performance playing a critical role.

Here Is what to consider for short-term trading:

The "Priced-in" Effect: The recent downward revision of analyst EPS estimates might suggest that some of the challenges are already priced into the stock. If Medtronic meets or slightly beats these lowered expectations, and more importantly, provides strong guidance, there could be a short-term rally.

Guidance is Key: For short-term traders, the company's forward-looking guidance is often a more significant catalyst than past performance. Upbeat guidance for fiscal 2026 could lead to a positive spike, while a conservative outlook, even with an earnings beat, could cause the stock to fall.

Technical Levels: Before earnings, it is wise to identify key support and resistance levels. A breakout above a resistance level on good news could signal a buying opportunity, while a breakdown below support on bad news could be a signal to short. The stock's recent performance has been in an uptrend, with some technical analysis pointing to immediate resistance near $91.50 and support around $87.

MDT is trading in consolidation and the resistance is now near $92.00 which could see that if there is any bad news or guidance provided suggest a challenging future quarters, we could see that MDT bulls losing control and move towards the 87 to 90 range.

Volatility: Earnings reports often increase volatility. Options traders could consider strategies like a straddle or a strangle to profit from a large move in either direction, but be aware of the high implied volatility.

Considering the high implied volatility, MDT implied volatility (IV) is 20.3, which is in the 60% percentile rank. This means that 60% of the time the IV was lower in the last year than the current level. The current IV (20.3) is -5.2% below its 20 day moving average (21.4) indicating implied volatility is trending lower. So I think a Bear Call Spread strategy might be suitable to take advantage a potential moderate decrease in share price after its earnings.

Summary

Medtronic (MDT) is set to report its fiscal Q1 2026 earnings on August 19, 2025. Analysts anticipate revenue of $8.37 billion, a 5.7% increase year-over-year, and flat adjusted earnings per share (EPS) of $1.23. A key point of caution is that EPS estimates have trended downward over the past 90 days, suggesting some challenges.

Investors should closely monitor segment performance, particularly in Neuroscience and Cardiovascular, which are expected to drive growth. The company's commentary on the "backend-loaded" growth for the full fiscal year and the impact of foreign exchange will be crucial. For short-term traders, the stock's reaction will heavily depend on both the results and any updates to its full-year guidance. Strong guidance could lead to a rally, while a conservative outlook might cause a decline, even if the company beats estimates.

Appreciate if you could share your thoughts in the comment section whether you think MDT would be able to weather the macroeconomic headwinds and provide a strong guidance which could see a price rally.

@TigerStars @Daily_Discussion @Tiger_Earnings @TigerWire @MillionaireTiger appreciate if you could feature this article so that fellow tiger would benefit from my investing and trading thoughts.

Disclaimer: The analysis and result presented does not recommend or suggest any investing in the said stock. This is purely for Analysis.